Growth RecoveryA significant percentage of children treated with Ojemda demonstrated growth recovery after a median follow-up, addressing a key concern.
Market MomentumReaffirming commercial trajectory: real-world momentum mirrors clinical confidence, with over 1,600 prescriptions written and $57.2M in net sales achieved, validating market readiness and unmet need.
Treatment PreferenceOjemda's once weekly dosing in an outpatient setting is preferred over chemotherapy, which requires blood transfusions and causes bone toxicity.